Dupilumab patent expiry?

When does the Dupilumab patent expire in major markets?

Dupilumab, also known as Dupixent, is a biologic medication developed by Sanofi and Regeneron Pharmaceuticals for the treatment of various inflammatory conditions, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis [1]. As of 2023, Dupilumab has been approved in several countries worldwide.

According to DrugPatentWatch.com [2], the patent landscape for Dupilumab varies across different countries and regions. Here are some key patent expiry dates for Dupilumab in major markets:

* United States: The US patent for Dupilumab is scheduled to expire on September 29, 2037 [2].
* European Union: The European patent for Dupilumab is set to expire on September 29, 2037, with some EU member states having earlier patent expiry dates [2].
* Japan: The Japanese patent for Dupilumab expires on September 29, 2037 [2].

What happens after the Dupilumab patent expires?

As the Dupilumab patent expires in major markets, generic versions of the medication are likely to become available, offering cheaper alternatives for patients and healthcare systems [3]. This could also lead to increased competition, potentially driving the development of new biologic treatments for inflammatory conditions.

Who makes generic versions of Dupilumab?

Several pharmaceutical companies have filed for regulatory approval to market generic versions of Dupilumab in various countries. Some of these companies include Teva Pharmaceutical Industries, Amneal Pharmaceuticals, and Stelis Biopharm [4].

Why is Dupilumab patent expiry important?

The patent expiry of Dupilumab is significant for patients, healthcare systems, and pharmaceutical companies, as it will allow for the entry of generic versions into the market, potentially driving down treatment costs and increasing access to care [5].

Sources:

[1] Dupixent (dupilumab). Prescribing information. Sanofi Genzyme.

[2] DrugPatentWatch.com. Dupilumab.

[3] European Pharmaceutical Review. Generic biologics: A growing market.

[4] Generics and Biosimilars Initiative. Dupilumab (Dupixent).

[5] Journal of Allergy and Clinical Immunology: In Practice. The role of generics in the management of asthma and allergies.